TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

Mid and South Essex NHS Trust has expanded the use of genomics across Southend, Basildon and Broomfield hospitals.

Germline testing is a genetic screening that looks for inherited gene mutations found in every cell.  It can identify ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

Prostate Cancer is the second leading cause of death in American men after lung cancer. In 2018, 165,000 men will be diagnosed with prostate cancer. The question all men with prostate cancer need ...

For Josh Henderson, 66, of Olympia, getting genetic testing was a no-brainer. “The first time I came to Fred Hutch, my oncologist suggested it,” said the retired IT manager who received a metastatic ...

Prostate cancer screening saves many more lives than earlier studies suggested, research shows. The results from the longest-running European trial show one life saved for every six men diagnosed, a ...